← back to search

Thomas E. Clancy

Harvard University · US
Area of research
Oncology · Cancer Research
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, and Cancer Immunotherapy and Biomarkers.
h-index
37
citations
10,335
works
400
NIH funding
primary concept
Medicine
email

Recent publications

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Clinical Cancer Research 2023cited by 45position: middledoi
Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer
Gut 2023cited by 35position: middledoi
Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors
Science Advances 2023cited by 31position: middledoi
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
Clinical Cancer Research 2023cited by 27position: middledoi
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity
Cancer Research 2022cited by 88position: middledoi
Spatially organized multicellular immune hubs in human colorectal cancer
Cell 2021cited by 794position: middledoi
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
Cell 2021cited by 578position: middledoi
AHPBA guidelines for managing VTE prophylaxis and anticoagulation for pancreatic surgery
HPB 2021cited by 29position: firstdoi
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Cancer Discovery 2018cited by 367position: middledoi
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer
Genetics in Medicine 2018cited by 216position: middledoi
Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer
Science 2017cited by 1,491position: middledoi
Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma
JAMA Oncology 2017cited by 269position: middledoi
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer
Nature Biotechnology 2014cited by 534position: middledoi
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
Cell Host & Microbe 2013cited by 2,669position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Craig L. Slingluff · University of Virginia Health System1 papers (2023–2023)Wendy S. Garrett · Harvard University1 papers (2013–2013)Jiping Wang · Discovery Institute1 papers (2023–2023)Dean E. Brenner · University of Michigan1 papers (2013–2013)Stephanie K. Dougan · Harvard University1 papers (2023–2023)Emad El‐Omar · Sutherland Hospital1 papers (2013–2013)Anuj Patel · Thomas Jefferson University1 papers (2023–2023)Matthew H. G. Katz · The University of Texas MD Anderson Cancer Center1 papers (2023–2023)Nipun B. Merchant · University of Miami1 papers (2023–2023)Patrick J. Lenehan · University of Connecticut1 papers (2023–2023) · 1 papers (2021–2021)Eunyoung Chun · Ewha Womans University1 papers (2013–2013)Rawad Elias · Baystate Health1 papers (2023–2023) · 1 papers (2023–2023) · 1 papers (2023–2023)Felipe B. Maegawa · Emory University1 papers (2021–2021)Thomas A. Abrams · Harvard University1 papers (2023–2023)Paul Lochhead · Massachusetts General Hospital1 papers (2013–2013)Jonathan N. Glickman · Harvard University1 papers (2013–2013)Brian M. Wolpin · Harvard University1 papers (2023–2023)